NCT05329506 is a clinical trial of patient population in Vaccinations, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05329506?

NCT05329506 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05329506?

Interventions in NCT05329506: patient population.

What condition does NCT05329506 study?

NCT05329506 studies Vaccinations.

Is NCT05329506 still recruiting?

NCT05329506 is currently completed. Last updated 17 July 2024.

Last reviewed 2024-07-17 · How we verify

NCT05329506

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Attitudes and Believes About Vaccinations in a Supportive Care Patient Population

Completed Last updated 17 July 2024

What this trial tests

trial testing patient population in Vaccinations in 104 participants. Completed in 15 July 2024.

Timeline

10 March 2022

Primary endpoint
15 July 2024

15 July 2024

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	104
Start date	10 March 2022
Primary completion	15 July 2024
Estimated completion	15 July 2024
Sites	1 location across United States

Drugs / interventions tested

patient population

Conditions studied

Vaccinations — all drugs for Vaccinations →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Vaccinations. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To learn about the attitudes and beliefs towards vaccination both before and after the COVID-19 pandemic in patients who have received supportive care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05329506 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 17 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05329506.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing